Project Grant R41AI192172
Award Date 8/18/25
Completion Date 7/31/26
Dollars Obligated $306K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
- This $307,091 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports the development of immune evasion technologies by Aleutian Therapeutics, Inc. to enable allogeneic cell therapies without the need for immunosuppressive drugs. The objective is to determine the minimum number of genetic edits required to allow human pluripotent stem cell-derived therapies to overcome immune rejection barriers like...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $300,000 Phase I SBIR grant to Optimeos Life Sciences, Inc. to develop an off-the-shelf nanoparticle platform for in vivo stem cell gene therapy to treat primary immunodeficiencies. The project aims to deliver a DNA payload in nanoparticles targeting hematopoietic stem and progenitor cells for gene replacement, with the initial focus on treating...
- This $380,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to the Regents of the University of Minnesota aims to develop optimized micellar nanoparticles (MNPs) for delivering binary base editor treatments (mRNA encoding an adenine base editor and guide RNA) to hematopoietic stem/progenitor cells in vivo. The goal is to advance a precision gene therapy approach for treating severe combined...
- This $300,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a GMP-compliant E. coli dihydrofolate reductase (EDHFR) vector. This vector will be used to monitor the biodistribution and trafficking of investigational chimeric antigen receptor (CAR) T cell therapies through positron emission tomography (PET) imaging. The goals are to provide a...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855), provides $919,501 to Emmune Inc. to develop a non-viral gene therapy platform for delivering the ECD4-IG therapeutic protein as a potential lifetime treatment for HIV. The key products and services funded under this 1-year award include conducting basic science experiments to inform the development of this...
- This Project Grant award of $118,488, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to develop HIV-resistant hematopoietic stem cells through targeted base editing. The award recipient, President and Fellows of Harvard College, will conduct two aims: 1) Identify CCR5 mutants that knock out CCR5 expression while decreasing CXCR4 cell surface expression, and 2) Identify CXCR4...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $152,324 Project Grant under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to The Leland Stanford Junior University. The funding supports research to define the role of the protein CXCL13 as an aging-associated defect in the homeostasis of memory T cells. The research strategy leverages human immune organoid technology to reveal the mechanism of CXCL13-mediated maintenance of memory T...
- This federal Project Grant award of $350,000 from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop polymer-derived biomaterials for messenger RNA (mRNA) delivery to induce antigen-specific immune tolerance. The award supports research to evaluate diverse nanocarrier formulations encapsulating antigens and mRNAs encoding tolerogenic proteins, investigate the biodistribution and...
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $405,497.00 to the University of Washington to develop a compact viral system for robust, concurrent CRISPR activation and interference (CRISPRa/i) in primary murine immune cells. The goal is to enable concurrent activation and repression of different genes in the same cell, in order to better elucidate gene regulatory networks underpinning T...
- This $420,771 federal Project Grant from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to develop a targeted genetic therapy for Artemis-deficient SCID, a form of primary immunodeficiency. The award, provided to the Regents of the University of Minnesota, aims to evaluate the feasibility of using an adenosine base editing approach to functionally restore a prevalent nonsense mutation in the Artemis gene and...